Immunome IMNM Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $582.69M-10.8% | $653.48M+140% | $272.64M+89.5% | $143.88M-44.2% | $257.61M+79.7% | ||
| $594.31M-10.1% | $660.78M+136% | $279.92M+0.9% | $277.43M-14.1% | $323.13M+46.0% | ||
| $17.08M+16.7% | $14.64M+26.6% | $11.56M+4.9% | $11.03M+0.7% | $10.95M+8.3% | ||
| $619.79M-9.3% | $683.19M+128% | $299.38M+1.0% | $296.29M-13.5% | $342.69M+42.6% | ||
| $5.53M+65.7% | $3.34M-45.7% | $6.15M+31.9% | $4.66M-48.9% | $9.13M-35.7% | ||
| —— | $0— | $0— | $0-100% | $4.02M-42.2% | ||
| $27.41M-39.1% | $44.99M+43.1% | $31.45M+37.4% | $22.88M-25.7% | $30.8M-43.3% | ||
| $31.11M-36.3% | $48.85M+37.8% | $35.46M+31.2% | $27.02M-24.0% | $35.57M-39.8% | ||
| $11K0.0% | $11K+22.2% | $9K0.0% | $9K0.0% | $9K+50.0% | ||
| -$782M-7.4% | -$728.16M-10.6% | -$658.26M-9.6% | -$600.81M-7.8% | -$557.41M-8.1% | ||
| $588.69M-7.2% | $634.34M+140% | $263.92M-2.0% | $269.27M-12.3% | $307.13M+69.5% | ||
| $619.79M-9.3% | $683.19M+128% | $299.38M+1.0% | $296.29M-13.5% | $342.69M+42.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Immunome cover its short-term obligations?
- Its current ratio is 21.68 — current assets exceed current liabilities.
- Where does Immunome's balance sheet data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.